Exhibit 99.1

 

 

Synthorx Reports Fourth Quarter and

Full Year 2018 Financial Results

Company Positioned for Upcoming 2019 Milestones After Successful IPO Raising $150.7 Million in Gross Proceeds

Presented Preclinical Safety and Anti-Tumor Data on Lead Product Candidate THOR-707 at SITC 33rd Annual Meeting; Expect to File Investigational New Drug (IND) Application in Second Quarter of 2019

 

SAN DIEGO, CA – March 12, 2019 – Synthorx, Inc. (Nasdaq: THOR), a biotechnology company using a unique Expanded Genetic Alphabet platform technology to discover and develop optimized biologics for cancer and autoimmune (AI) disorders, today reported financial results and provided a business update for the fourth quarter and full year ended December 31, 2018.

 

“2018 was a transformative year for Synthorx. With the proceeds from our initial public offering in December and Series C financing earlier in the year, we are well-positioned to enter the clinic in 2019 with our lead IL-2 immuno-oncology (IO) SynthorinTM, THOR-707, and build our pipeline as we advance additional IO cytokines and our IL-2 AI Synthorin product candidate into preclinical development,” said Laura Shawver, president and chief executive officer. “We are off to an excellent start to 2019 as we recently completed a GMP fermentation of THOR-707 and expect to file our IND in the second quarter of 2019.”

 

Fourth Quarter 2018 and Other Recent Highlights

 

Completed initial public offering and closed second tranche of Series C. In December 2018, Synthorx completed an initial public offering, selling 13,699,636 shares at a public offering price of $11.00 per share, raising net proceeds of $137.5 million. In addition, in November 2018, the Company completed the second closing of its Series C financing, raising net proceeds of $37.1 million.

 

Presented Preclinical Data at SITC.  In November 2018, Synthorx presented results of preclinical studies demonstrating the safety and anti-tumor effects of THOR-707 for the treatment of solid tumors at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting. In in vivo studies, THOR-707 was shown to induce molecular markers of T cell activation and the proliferation of peripheral NK and CD8+ effector T cells without signs of vascular leak syndrome.

 

Began GLP-tox studies of THOR-707. In the fourth quarter, the company completed scale up of THOR-707 through a third-party manufacturer and began IND-enabling toxicology studies at a contract laboratory

 


The following information was filed by Synthorx, Inc. (THOR) on Tuesday, March 12, 2019 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Synthorx, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Synthorx, Inc..

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Log in with your credentials

or    

Forgot your details?

Create Account